Clinical Trial Update: Pembrolizumab in the Treatment of Advanced, Progressive Adrenocortical Carcinoma. [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating pembrolizumab for advanced, progressive adrenocortical carcinoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adrenocortical Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology | Conditions: Adrenocortical Carcinoma | Phase 2 | Status: RECRUITING